Abstracts tagged "Rheumatoid Factor"

Abstract Number: 1607 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Is Associated with the Distribution of Hand Joint Destruction in a Dose-Dependent Manner
Chikashi Terao¹, Noriyuki Yamakawa², Koichiro Yano³, I.M. Markusse⁴, Katsunori Ikari³, Shinji Yoshida³, Moritoshi Furu⁵, Motomu Hashimoto⁵, Hiromu Ito⁵, Takao Fujii⁶, Koichiro Ohmura⁷, Kosaku Murakami⁷, Meiko Takahashi², Masahide Hamaguchi⁸, Yasuharu Tabara², Atsuo Taniguchi³, Shigeki Momohara³, Soumya Raychaudhuri⁹, Cornelia F. Allaart¹⁰, Hisashi Yamanaka¹¹, Tsuneyo Mimori¹² and Fumihiko Matsuda¹³, ¹Departments of Genetics and Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴LUMC, Leiden, Netherlands, ⁵Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Dept of Rheum & Clinical Immun, Kyoto Univ Grad School of Med, Kyoto, Japan, ⁸Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan, ⁹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁰Rheumatology, LUMC, Leiden, Netherlands, ¹¹Tokyo Women's Medical University, Tokyo, Japan, ¹²Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ¹³Genomic Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease leading to joint destruction. Although many studies have addressed correlates associated with the speed of joint destruction,…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 1740 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Inflammatory Bowel Disease
Jaita Mukherjee¹, Maria Mouyis¹, Kavina Shah¹, Mohammad Mahdi Saeidinejad¹, Ayesha Akbar² and Shahir Hamdulay¹, ¹Rheumatology, Northwick Park Hospital, Middlesex, United Kingdom, ²Gastroenterology, Northwick Park Hospital, Middlesex, United Kingdom
Background/Purpose: Enteropathic arthropathy refers to the pattern of inflammatory arthritis seen in association with gastrointestinal pathology. Arthritis in the presence of inflammatory bowel disease can…
Abstract Number: 2257 • 2015 ACR/ARHP Annual Meeting
Decline of Lung Function Is Associated with the Presence of Rheumatoid Factor in Korean Health Screening Subjects without Clinically Apparent Lung Diseases
Jiwon Hwang¹, Jae-Uk Song², Hyungjin Kim³, Hyemin Jeong⁴, Yeong Hee Eun⁵, Chan Hong Jeon⁶, Ji-Min Oh⁷, Jaejoon Lee⁴, Hoon-Suk Cha⁸, Eun-Mi Koh⁵ and Joong Kyong Ahn⁹, ¹Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, South Korea, ³Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁷Anyang SAM Hospital, Anyang, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc component of IgG. It is present in approximately 70-80% of rheumatoid arthritis (RA) patients…
Abstract Number: 2372 • 2015 ACR/ARHP Annual Meeting
Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Alberto Sifuentes Giraldo¹, Carlo Alberto Scirè², Santos Castañeda³, Laura Nuño⁴, Francisco Javier Lopez Longo⁵, Julia Martínez-Barrio⁵, Franco Franceschini⁶, Ilaria Cavazzana⁶, Paolo Airò⁷, Elena Bartoloni Bocci⁸, Javier Bachiller Corral⁹, Rossella Neri¹⁰, Simone Barsotti¹¹, Roberto Caporali¹², Carlomaurizio Montecucco¹³, Marcello Govoni¹⁴, Renato La Corte¹⁴, Federica Furini¹⁴, Florenzo Iannone¹⁵, Margherita Giannini¹⁶, Enrico Fusaro¹⁷, Simone Parisi¹⁸, Giuseppe Paolazzi¹⁹, Giovanni Barausse¹⁹, Raffaele Pellerito²⁰, Alessandra Russo²⁰, Lesley Ann Saketkoo²¹, Norberto Ortego-Centeno²², Luca Quartuccio²³, Christof Specker²⁴, Andreas Schwarting²⁵, Kostantinos Triantafyllias²⁶, Carlo Selmi²⁷, Fausto Salaffi²⁸, Marco Amedeo Cimmino²⁹, Annamaria Iuliano³⁰, Fabrizio Conti³¹, Gianluigi Baiocchi³², Elena Bravi³³, Veronica Codullo¹², Anna Ghirardello³⁴, Trinitario Pina³⁵, Miguel Angel Gonzalez-Gay³⁵, Lorenzo Cavagna¹³ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ²Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹³Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁶DIM, Rheumatology Unit, Bari, Italy, ¹⁷Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁸Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ¹⁹Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²⁰Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²²Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ²³Clinic of Rheumatology, Department of Medical and Biological Sciences (DSMB), Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ²⁴Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁶ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ²⁸Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ²⁹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³⁰Osp. San Camillo, Roma, Italy, ³¹Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³²Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³³Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁴Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) are reported in up to 90% of patients affected by antisynthetase syndrome (ASSD) and thus represent the…
Abstract Number: 2441 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis
Alan M. Rosenberg¹, Walter Maksymowych², Yuan Gui³ and Anthony Marotta³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp., Vancouver, BC, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a collective term used to denote clinically discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis, Polyarthritis, Psoriatic arthritis, Systemic arthritis…
Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 2450 • 2015 ACR/ARHP Annual Meeting
Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis
Lance Feller¹, Austin M. Dalrymple², Paul Tuttle IV³, Reema H. Syed³, Peri Pepmueller¹ and Terry Moore⁴, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Pediatric Rheumatology, St. Louis University, St. Louis, MO, ³IM-Rheumatology, Saint Louis University, St. Louis, MO, ⁴Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 495 • 2015 ACR/ARHP Annual Meeting
Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Antonio Manzo¹, Serena Bugatti¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Barbara Vitolo¹, Carlomaurizio Montecucco¹ and Roberto Caporali², ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of the…
Abstract Number: 2607 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke
Raymundo Vera-Pineda¹, Alberto Cardenas-de La Garza², Jorge Esquivel-Valerio³, Dionicio A. Galarza-Delgado², Jose Ramon Azpiri-Lopez⁴, Iris J. Colunga-Pedraza², Mario Alberto Garza-Elizondo² and Jesus Zacarias Villarreal-Pérez⁵, ¹Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ²Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ³Rheumatology, Hospital Universitario.UANL, Monterrey, Mexico, ⁴Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Endocrinology, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Tobacco smoke has been associated to anti-cyclic citrullinated peptide (anti-CCP) antibodies positivity. Recently, in wood-smoke-induced chronic obstructive pulmonary disease (COPD) patients without rheumatoid arthritis…
Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting
Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Nathalie Carrier¹, Anthony Marotta², Artur de Brum-Fernandes^3,4, Patrick Liang^3,4, Ariel Masetto^5,6, Yuan Gui², Jane Savill², Sara Michienzi², Henri Ménard⁷, Walter Maksymowych⁸ and Gilles Boire⁴, ¹Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…
Abstract Number: 551 • 2015 ACR/ARHP Annual Meeting
Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
R Alten¹, HG Nüßlein², M Galeazzi³, H-M Lorenz⁴, X Mariette⁵, A Cantagrel⁶, M Chartier⁷, G Desachy⁸, C Poncet⁹, C Rauch¹⁰ and M Le Bars¹¹, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Erlangen, Nürnberg, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵Université Paris-Sud, Paris, France, ⁶Purpan Hospital, Toulouse, France, ⁷Chiltern International, Neuilly, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Docs International, Nanterre, France, ¹⁰Bristol-Myers Squibb, Munich, Germany, ¹¹Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In a recent meta-analysis, neither rheumatoid factor (RF) nor anti-cyclic citrullinated peptide (anti-CCP) antibody status were associated with clinical response to treatment with anti-TNF…
Abstract Number: 2676 • 2015 ACR/ARHP Annual Meeting
Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Alejandro Garza-Alpirez¹, Mario Alberto Garza-Elizondo², David Vega-Morales², Cassandra Skinner-Taylor², Ricardo Ramírez³, Roberto Negrete-López⁴, Jorge Esquivel-Valerio², Miguel Villarreal-Alarcon² and Andrés Mendiola¹, ¹Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario " Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].